- Home
- NUVL vs HALO Comparison
NUVL vs HALO Comparison
Compare NUVL & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUVL | HALO |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | 228 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.8B |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | NUVL | HALO |
|---|---|---|
| Price | $110.87 | $66.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 11 |
| Target Price | ★ $134.75 | $78.64 |
| AVG Volume (30 Days) | 454.3K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | N/A | $28.24 |
| Revenue Next Year | $1,239.49 | $12.56 |
| P/E Ratio | ★ N/A | $56.30 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.14 | $51.06 |
| 52 Week High | $113.02 | $82.22 |
Technical Indicators
Market Signals| Indicator | NUVL | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 64.36 | 47.79 |
| Support Level | $97.99 | $62.53 |
| Resistance Level | $112.61 | $69.95 |
| Average True Range (ATR) | 3.54 | 2.55 |
| MACD | 0.84 | -0.07 |
| Stochastic Oscillator | 92.70 | 32.24 |
Price Performance
Historical ComparisonAbout NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.